Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

Articles published by Merck & Co., Inc. Merck

Merck’s KEYTRUDA® (pembrolizumab) Approved in China in Combination With Chemotherapy as Neoadjuvant Treatment, Then Continued as Monotherapy After Surgery as Adjuvant Treatment for Patients With Resectable Stage II, IIIA or IIIB NSCLC
From Merck & Co., Inc. Merck
Via Business Wire
Tickers MRK
U.S. District Court Rules In Favor of Merck in Sitagliptin Phosphate Patent Lawsuit
From Merck & Co., Inc. Merck
Via Business Wire
Tickers MRK
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.